BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-10 out of 596 found
  Current Search:      

HTML
100%
Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
NEW BRUNSWICK, N.J., July 3 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced that the initial offering period of its tender offer for all outstanding shares of common stock of Cougar Biotechnology, Inc.

(Nasdaq:...

Biz Journals:  Jul 3 2009 2:22PM Find similar documents
HTML
100%
BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis
TURKU, Finland, July 3 /PRNewswire/ -- BioCis Pharma Ltd., a privately held drug development company with its headquarters in Turku, Finland, announced positive results from its Phase IIa clinical trial of ProtoCure(TM) emulsion cream, the...
Biz Journals:  Jul 3 2009 12:47PM Find similar documents
HTML
100%
J&J to invest $1.5B in Elan, new venture
will invest $1 billion for an 18.4 percent stake in Irish drug maker Elan Corp., which has its U.S.

headquarters in South San Francisco.

The companies also said they will form a new venture for development of Elan and Wyeths Alzheimers...

Biz Journals:  Jul 2 2009 9:43PM Find similar documents
HTML
100%
Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported
PHILADELPHIA, July 2 /PRNewswire-USNewswire/ -- A new analysis of the incidence of breast cancer in Italy per 100,000 women between the ages of 0 to 84 from 2000 to 2005 shows a 72 percent spike above official estimates issued by the...
Biz Journals:  Jul 2 2009 9:39PM Find similar documents
HTML
100%
Arca Biopharma CEO resigns
Arca Biopharma, which last month saw its heart failure drug Gencaro rejected by the Food and Drug Administration, said CEO Richard Brewer will resign effective July 10.

Arca (NASDAQ: ABIO), based in Broomfield, Colo., earlier this year...

Biz Journals:  Jul 2 2009 9:32PM Find similar documents
HTML
100%
Genentech drug does well in blindness test
Genentech Inc.

said a Phase III study of Lucentis in patients with swelling of the eye caused by branch retinal vein occlusion a common cause of blindness showed that the drug improved vision.

The San Francisco-based, wholly owned...

Biz Journals:  Jul 2 2009 8:50PM Find similar documents
HTML
100%
ACT Announces Partnership With Gilead Sciences Inc
SUNNYVALE, Calif., July 2 /PRNewswire/ -- Advanced Chemical Transport, one of the leading environmental companies in California, has announced a multi-year partnership with Gilead Sciences Inc., North America's third largest Bio-Med company....
Biz Journals:  Jul 2 2009 7:40PM Find similar documents
HTML
100%
Johnson & Johnson pays $1B for Elan stake, Alzheimers drugs
has bought an 18.4 percent stake in Irish drugmaker Elan for $1 billion in a deal that also gives J&J rights to four Alzheimers disease treatments still in clinical trials.

The Alzheimers drugs are being developed by a partnership of...

Biz Journals:  Jul 2 2009 7:30PM Find similar documents
HTML
100%
Stem cell organizations form D.C. lobby
Thirteen universities, life sciences companies, health care investors and patient advocates have formed a Washington, D.C., group to support stem cell research.

The aims to advance stem cell research before policy makers, the media and the...

Biz Journals:  Jul 2 2009 2:37PM Find similar documents
HTML
100%
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
PARIS, July 2 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S.

Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets.

Patients with atrial fibrillation ...

Biz Journals:  Jul 2 2009 1:52PM Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.